Skip to content

Relay Therapeutics

US · RLAY #2273 by market cap Listed 2020
17.95 -0.79 -4.22%
Live - 5344 symbols - heartbeat 442s ago · 2026-10-08 07:00
Pre-market 17.84 -0.61%
After-hours 17.95 0.00%
Overnight 17.95 0.00%
Market cap
3.93B
P/B
4.42
EPS
-1.61
Reader sentiment Are you bullish or bearish on RLAY?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    Guggenheim Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $26
    Market Newswire · 2026/5/26
  • Rating change
    CCORF Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $29
    Market Newswire · 2026/8/8
  • Citizens JMP Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $26
    Market Newswire · 2026/8/10
  • Rating change
    Citizens JMP Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $21
    Market Newswire · 2026/5/21
  • Rating change
    Goldman Sachs Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $31
    Market Newswire · 2026/7/22
  • Rating change
    A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $20 to $27
    Market Newswire · 2026/5/20
  • Rating change
    Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $30
    Market Newswire · 2026/8/7
  • Rating change
    Oppenheimer Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $18
    Market Newswire · 2026/5/6
  • Rating change
    A Quick Look at Today's Ratings for Relay Therapeutics(RLAY.US), With a Forecast Between $18 to $21
    Market Newswire · 2026/5/6
  • H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $29
    Market Newswire · 2026/8/20
  • Rating change
    Analysts Are Bullish on These Healthcare Stocks: BrightSpring Health Services, Inc. (BTSG), Relay Therapeutics (RLAY)
    TipRanks · 2026/6/18
  • J.P. Morgan Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $31
    Market Newswire · 2026/8/14
  • Rating change
    Barclays Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $27
    Market Newswire · 2026/5/21
  • Rating change
    H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Raises Target Price to $28
    Market Newswire · 2026/5/26
  • Rating change
    J.P. Morgan Maintains Relay Therapeutics(RLAY.US) With Buy Rating
    Market Newswire · 2026/8/4
  • Rating change
    TD Cowen Maintains Relay Therapeutics(RLAY.US) With Buy Rating
    Market Newswire · 2026/8/7
  • JonesTrading Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $20
    Market Newswire · 2026/9/28
  • Rating change
    Goldman Sachs Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $22
    Market Newswire · 2026/6/3
  • Rating change
    CCORF Initiates Relay Therapeutics(RLAY.US) With Buy Rating, Announces Target Price $29
    Market Newswire · 2026/7/16
  • H.C. Wainwright Maintains Relay Therapeutics(RLAY.US) With Buy Rating, Maintains Target Price $29
    Market Newswire · 2026/8/21

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 07:00:27 · For reference only, not investment advice and not tailored to your situation.